

7th EMGM meeting – LANZAROTE (SPAIN)

24-27 September 2003

Organized by the Spanish Reference Laboratory for Meningococci from the National Center for Microbiology and by the Unit of Epidemiological Surveillance from the National Center for Epidemiology. Both centres belong to the National Institute of Health Carlos III.

Especial thanks to those people from the “Servicio Canario de Salud” that has been working hardly in several of the logistic areas for the meeting.



FINANTIAL SUPPORT:

MAJOR SPONSORS:

- WYETH LEDERLE VACCINES**
- CHIRON**

SPONSORS:

- BAXTER MEDICAL AB**
- GLAXO-SMITHKLINE (GSK)**
- INSTITUTO DE SALUD CARLOS III**
- TOWN COUNCIL OF THE CITY OF TEGUISE**
- CABILDO OF LANZAROTE**
- AVENTIS-PASTEUR**

Final Programme

24th September

People arriving throughout the day

17h00-19h00

Parallel Simposium. Paula Kriz and Mary Cafferkey.

State of the art of the strategies to develop a group B vaccine .

- ❖ **Fletcher**, Mark from Wyeth Vaccines Research, Puteaux-Paris La Defense, France.
- ❖ **Reddin**, Karen M from the Health Protection Agency, Porton Down, Salisbury, UK
- ❖ **Rappuoli**, Rino from the IRIS Research Centre, Chiron, Siena, Italy.
- ❖ **van den Dobbelseen**, Germie from the Netherlands Vaccine Institute, Bilthoven, The Netherlands
- ❖ **Wedge**, Elisabeth from Norwegian Institute of Public Health, Oslo, Norway.
- ❖ **Weynants**, Vincent from GlaxoSmithKline Biologicals, Rixensart, Belgium.

19h30 Wellcome Cocktail in the Hotel Occidental Allegro Oasis

OFFICIAL PROGRAMME

25th September

8:30-8:45 Wellcome: The organisers

8:45-9:15, Andrew J. Fox “Where did we start from, where are we now and where are we going in the future”

9:15-9:30 Sarah Handford and Mathias Frosch. Overview of EU-Ibis/MenNet

9:30-11:00 Sarah Handford and Andrew J. Fox

- **Session Epidemiology**

Overview of Meningococcal disease epidemiology in EU

SELECTED ORAL PRESENTATIONS

- ❖ E.B.Kaczmarek¹, S.J.Gray¹, A.J.Fox, M.Ramsay² et al. An overview of the current epidemiological situation for meningococcal disease in England and Wales
- ❖ Belén Alcalá, L. Arreaza, C. Salcedo, R. Abad, MJ Uría, R. Enríquez & JA Vazquez. Analysis of the spread in Spain of B:2a:P1.5 meningococcal strains probably originated by capsular switching mechanisms.
- ❖ Marjolein Damen and Arie van der Ende. The population structure of invasive *Neisseria meningitidis* in the Netherlands, 2001.
- ❖ Muhamed-Kheir Taha* and Jean-Michel Alonso. Evolution of invasive strains of serogroup W135 in France since 2000.
- ❖ P. Mastrantonio*, P. Stefanelli, T. Sofia, C. Fazio, A. Neri, M. G. Caporali and S. Salmaso. Invasive Meningococcal Disease in Italy in the years 2001-2002

11:00-11:30 Coffee

11:30-13:00 Andrew J Fox and Muhamed-K Taha

- **Session Quality Assurance/reference laboratory issues**

Strain characterisation-Phenotypic/genotypic QA

Non Culture Diagnosis QA

SELECTED ORAL PRESENTATIONS

- ❖ Konstantinos Kesanopoulos*, Georgina Tzanakaki, Jenny Kremastinou. Evaluation of touch-down Real-time PCR for the detection of *N. meningitidis* in clinical samples.
- ❖ A.B. Gjini*, J. M. Stuart, K.A.V. Cartwright, J. Cohen, S.K. Granier, Michael Jacobs, T Nichols, N. Ninis, H. Prempeh, Andrew Whitehouse, R. S. Heyderman. Community acquired acute bacterial meningitis and meningococcal septicaemia in adults: an audit on diagnosis and management.

13:00-14:30 Lunch

15h00-16h00 Colin Block and Julio A. Vázquez

- **Session Antibiotic resistance**

Questionnaire about impact of EMGM recommendations

Improving the data for antibiotic resistance

Data base for the PenA gene sequence

SELECTED ORAL PRESENTATIONS

- ❖ Aude Antignac*, Ivo Gomperts Boneca, Jean-Michel Alonso and Muhamed-Kheir Taha. Structural modifications of meningococcal peptidoglycan are linked to reduced susceptibility to penicillin G

- ❖ S.Tyski*, W. Grzybowska. The detection of penicillin insensitivity in *Neisseria meningitidis* by polymerase chain reaction.
- ❖ B. Alcalá*, R. Abad, L. Arreaza, R. Enriquez, C. Salcedo, MJ Uría, & JA Vázquez. PCR as tool for detection of meningococcal strains with intermediate resistance to penicillin G
- ❖ Paola Stefanelli*, Alessandra Carattoli, Arianna Neri, Cecilia Fazio & Paola Mastrantonio. Prediction of penicillin decreased susceptibility in *Neisseria meningitidis* strains by Real-Time PCR.

16:00-16:30 Coffee

16:30-17:30 Ray Borrow and Germie van den Dobbelaar

- **Session Serology**

Protocols to be used

Identification of laboratories interested in serology

Possible QA

SELECTED ORAL PRESENTATIONS

- ❖ Diana Martin* , Anne Glennie, Lisa McCallum, Einar Rosenqvist, Arne Hoiby, Ingeborg Aaberge, George Santos, Philipp Oster, Jamie Findlow, Ray Borrow. Validating the serum bactericidal assay for group B meningococci for use in clinical trials
- ❖ Lal G, Balmer P*, Harrison T, Dawson M, Borrow R. Multiplex assay for the simultaneous quantification of antibodies to meningococcal serogroups A, C, W135 and Y in sera.
- ❖ Giuliani Marzia Monica*, Biolchi Alessia, Santini Laura, Brunelli Brunella, Pizza Mariagrazia, Rappuoli Rino. Antibody-dependent bactericidal activity against group B *Neisseria meningitidis* as a tool to test the protective activity of recombinant antigens against genetically diverse clinical isolates

17:30-18:00 Sigrid Heuberger and Arijana Boras

- **Results of The Questionnaire : Main Topics in which the emerging Reference Labs are interested in.**

18:00-18:30 Per Olcen and Eric Bertherat.

WHO/EMGM relationship.

- ❑ Per Ölcen. Meningonet, a WHO initiative: the idea and present level of development
- ❑ Eric Bertherat. Overview of meningitis in Africa: epidemiology and main issues of control.
- ❑ Amin Meshkas. Overview of meningitis in Saudi Arabia

20:00 Departure in buses for the dinner

26th September

9:00-10:30 Mary Ramsay and Rosa Cano

Session Vaccine policy

Overview of meningococcal disease group C vaccination across Europe

SELECTED ORAL PRESENTATIONS

- ❖ Anne Perrocheau on behalf of the InVs surveillance team for meningococcal disease. Outbreaks of C meningococcal disease in France – Implications for vaccination policy.
- ❖ F. Carion, G. Hanquet*, J-M. Collard. Epidemiology of meningococcal c disease in Belgium one year after a mass immunization campaign.
- ❖ Amparo Larrauri*, Rosa Cano, Salvador de Mateo. Meningococcal disease in Spain. Results of the disease surveillance two seasons after the conjugate vaccine was introduced .
- ❖ Caroline Trotter*, John Edmunds, Mary Ramsay, Rosa Cano, Sigrid Heuberger, Robert Welte, Hester de Melker, Lodewijk Spanjaard. Cost-effectiveness of meningococcal serogroup C conjugate vaccination in Europe.
- ❖ A. Menon, M. Cafferkey, K. Murphy, M. Fitzgerald, J. Devlin, D. O’Flanagan. The epidemiology of invasive meningococcal disease and the impact of the meningococcal c vaccine in Ireland.
- ❖ A. van der Ende, L. Spanjaard and J. Dankert. Epidemiology of meningococcal disease in the Netherlands: effect of vaccination against serogroup C meningococci.

10:30 –11:30 Ian Feaver and Steve Gray

Session Typing/Strain Characterization

Overview about typing strains.

SELECTED ORAL PRESENTATIONS

- ❖ Caroline Vipond, Janet Suker and Ian Feavers. Current Status Of And Future Plans For Monoclonal Antibody Reagents Available From NIBSC
- ❖ Diggle MA and Clarke SC. Multi-locus sequence analysis indicates that the clonal population of meningococci has changed since the introduction of meningococcal serogroup C polysaccharide conjugate vaccines
- ❖ Heike Claus, Hanne Weinand, Matthias Frosch, Ulrich Vogel. Use of monoclonal antibodies for the identification of clonal lineages of meningococci
- ❖ Paula Mölling*, Angela Steen, Susanne Jacobsson, Hans Fredlund and Per Olcén. Routine genosubtyping by sequencing the three variable regions within the *porA* gene of *Neisseria meningitidis* isolates during 2002 in Sweden.
- ❖ Martin Musilek*, Paula Kriz, Jitka Kalmusova, Renata Haugvicova, Jurgen Fesberg, Dominique A. Caugant. Changing clonal distribution of Czech invasive *Neisseria meningitidis* isolates

11:30-12h00 Coffee

12:00-13:00 Dominique Caugant and Georgina Tzanakaki

Carriers: what information offer carrier studies

SELECTED ORAL PRESENTATIONS

- ❖ Dominique A. Caugant*, Siamak P. Yazdankhah, Paula Kriz, Georgina Tzanakaki, Konstantinos Kesanopoulos, Martin C. J. Maiden, Keith Jolley. Multilocus sequence typing (MLST) of *Neisseria meningitidis* isolates from carriers and patients in the Czech Republic, Greece and Norway
- ❖ Paula Kriz*, Jitka Kalmusova, Martin Musilek, Renata Haugvicova, Jürgen Felsberg, Jana Vlkova. Prospective carriage study in the Czech Republic: duration of carriage and multiple carriage of *Neisseria meningitidis*.
- ❖ Georgina Tzanakaki*, Konstantinos Kesanopoulos, Fani Markou, Dominique A. Caugant, Siamak Yazdankhah, Jenny Kremastinou. Measurement of the multiple carriage in University students.

- ❖ James Stuart* and Hilary Orr. Saliva at low risk of transmitting meningococci.
- ❖ Delia Boccia, James Stuart*, Susanne Samuelsson, Sigrid Heuberger, Nick Andrews, Bernadette Purcell. Do antibiotics to nursery children after a single case of meningococcal disease reduce the risk of further cases?
- ❖ Gray SJ* & Clarke SC. Phenotypic characterisation of *Neisseria meningitidis* isolates collected in the UK from 15–18 year-olds before and after the introduction of serogroup C polysaccharide conjugate vaccine.

13:00-13:30

Conclusions and Nomination of the organiser country for EMGM 2005

13:30-15:00 Lunch

**15:00 Departure for a panoramic view of the island
Closing dinner in a “volcanic cavern”**

27th Departure of people

NOTE: Posters will be set up on the evening of September 24th and removed on the afternoon of September 26th.

SIZE OF THE POSTERS WILL BE 150 CM (HEIGHT) x 90 CM (WIDTH)

The organizers will provide resources to put up the posters.